TNFα depleting therapy improves fertility and animal welfare in TNFα-driven transgenic models of polyarthritis when administered in their routine breeding.

ABSTRACT: Transgenic tumour necrosis factor alpha (TNFα)-driven models of polyarthritis such as the TNF^ΔARE mouse have proven to be invaluable in delineating aspects of inflammatory disease pathophysiology in humans. Unfortunately, the onset of joint destruction and inflammation in these models represents a significant detriment to breeding management. We examined whether TNFα depleting therapy 'infliximab' might represent a significant refinement in routine breeding. Clinical scores of joint inflammation were assessed in TNF^ΔARE males receiving either infliximab (10 mg/kg) or saline by twice-weekly intraperitoneal injection. Joint histology and bone morphology were assessed by histological analysis and micro-computed tomography (CT), respectively. Analysis of breeding was exam

SUBMITTER: Naylor AJ 

PROVIDER: S-EPMC5802519 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature